WOONSOCKET, R.I., Nov. 20, 2014 /PRNewswire/ — CVS Health (NYSE: CVS) today announced that the company and its foundation has committed to invest more than $1 million in grants to support tobacco cessation and prevention programs. The grants will be distributed to leading health care and community partners working to promote tobacco-free communities, programs that […]
GE Healthcare to offer Caradigm’s Identity and Access Management suite with Omnyx digital pathology solutions to streamline pathology workflows. PITTSBURGH, PA – November 19, 2014 – GE Healthcare, a leader in technology innovation, today announced it will resell Caradigm’s Single Sign-On and Context Management solutions in the United States, Canada, and specific EU countries to […]
Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 WHITEHOUSE STATION, N.J., November 3, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation […]
WOONSOCKET, R.I., Nov. 19, 2014 /PRNewswire/ — CVS Health announced today that it received a score of 100 percent on the 2015 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related to LGBT workplace equality, administered by the Human Rights Campaign Foundation. CVS Health’s satisfaction of all of […]
Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent Amgen to Webcast Investor Call at AHA Scientific Sessions 2014 THOUSAND OAKS, Calif., Nov. 18, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational […]
Once-Daily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 18, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first […]
Data are Embargoed by American Heart Association until 10:45 AM CT Today WHITEHOUSE STATION, N.J., November 17, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data […]
CHICAGO, November 17, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN® (ezetimibe/simvastatin) – which combines simvastatin with the non-statin ZETIA® (ezetimibe) — experienced significantly fewer major […]
SOUTH SAN FRANCISCO, Calif. NOVEMBER 17, 2014 – Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced that the company has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN). The purpose of the agreement is to commercialize an in vitro diagnostic (IVD) kit that will enable clinical […]
KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH, November 16, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 […]